Warner Chilcott Takes Itself Off The Market; Special Dividend Disappoints
This article was originally published in The Pink Sheet Daily
Executive Summary
Warner Chilcott has ended all discussions with parties potentially interested in buying the company and tried to satisfy investors with a special dividend as a consolation prize.
You may also be interested in...
Tax Benefits, Branded Portfolio, Synergies Drive Actavis’ Acquisition of Warner Chilcott
Actavis’ purchase of Warner Chilcott will lower the former’s overall tax rate significantly, expand its specialty pharma business to 25% of total revenues, and provide global critical mass – all necessary responses to a future that includes fewer opportunities for small molecule generics and greater pricing pressures.
Merger With Warner Chilcott Expected To Turn Actavis Into #3 Specialty Pharma In U.S.
The rumored combination of Actavis and Warner Chilcott, with Actavis to re-domicile as an Irish firm for tax benefits, came to fruition May 20. Warner Chilcott CEO Boissonneault said the deal resulted from a long friendship with Actavis’ Bisaro and did not come together overnight.
Deals Of The Week: Keeping Score – Valeant Wants Actavis, Which Covets Warner Chilcott …
Meanwhile, companies like Mylan and Novartis also reportedly have joined the Actavis chase. In addition, there’s been deal-making news from Elan and Theravance, Merck-Serono and Quintiles, and AbbVie and Alvine.